+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study



Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study



British Journal of Clinical Pharmacology 85(9): 1984-1993



We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solution (TIS) using the I-neb device to the standard PARI-LC Plus nebulizer in children with cystic fibrosis. A randomized, open-label, crossover study was performed. In 2 separate study visits, blood samples from 22 children were collected following TIS nebulization with I-neb (75 mg) and PARI-LC Plus (300 mg). Study visits were separated by 1 month, in which 1 of the study nebulizers was used twice daily. Tobramycin PK for both nebulizers was established using measured tobramycin concentrations and Bayesian PK modelling software. Hearing and renal function tests were performed to test for aminoglycoside associated toxicity. In addition to standard estimated glomerular filtration rate values, biomarkers for tubular injury (KIM-1 and NAG) were measured. Patient and nebulizer satisfaction were assessed. Inhalations were well tolerated and serum trough concentrations below the predefined toxic limit were reached with no significant differences in PK parameters between nebulizers. Results of audiometry and estimated glomerular filtration rate revealed no abnormalities. However, increased urinary NAG/creatinine ratios at visit 2 for both nebulizers suggest TIS-induced subclinical tubular kidney injury. Nebulization time was 50% shorter and patient satisfaction was significantly higher with the I-neb. Nebulization of 75 mg TIS with the I-neb in children with cystic fibrosis resulted in comparable systemic exposure to 300 mg TIS with the PARI-LC Plus and was well tolerated and preferred over the PARI-LC Plus. Long-term safety of TIS nebulization should be monitored clinically, especially regarding the effects on tubular kidney injury.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066805307

Download citation: RISBibTeXText

PMID: 31112621

DOI: 10.1111/bcp.13988


Related references

WS14.3 Tobramycin nebulization with the I-neb in children with cystic fibrosis (TONI study): pharmacokinetics and safety. Journal of Cystic Fibrosis 16: S25-S26, 2017

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Journal of Cystic Fibrosis 8(5): 332-337, 2009

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Pulmonary Pharmacology and Therapeutics 26(2): 249-255, 2013

Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization. Journal of Aerosol Medicine and Pulmonary Drug Delivery 29(3): 273-280, 2016

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Therapeutic Advances in Respiratory Disease 11(7): 249-260, 2017

Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 112(5): 1208-1213, 1997

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatric Pulmonology 42(4): 307-313, 2007

Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatric Infectious Disease Journal 16(6): 572-578, 1997

The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. Journal of Antimicrobial ChemoTherapy 42(1): 103-106, 1998

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatric Drugs 9(Suppl. 1): 11-20, 2007

Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized withPseudomonas aeruginosa. Paediatric Drugs 9(1 Suppl.): 11-20, 2007

Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. Journal of Cystic Fibrosis 13(4): 428-434, 2014

Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic Fibrosis 7(2): 142-146, 2008

Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. Journal of Antimicrobial ChemoTherapy 71(3): 711-717, 2016

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128(4): 2336-2346, 2005